An observational study in Type 2 Diabetes (T2DM), sponsored by Shanghai 6th People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Shanghai 6th People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital — 6 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai 6th People's Hospital.
Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 11th registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 60+
Shanghai 6th People's Hospital
Ages 18–70
Shanghai 6th People's Hospital
Ages 35–70
By country, each count listing its studies:
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is below the median of 300 across 1,746 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 150 across the 8 interventional studies, 225 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai 6th People's Hospital is the lead sponsor of 70 studies on the registry; 39 are open to participants now.
5 of the studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07288372Shanghai 6th People's HospitalThe CGM-OGTT Glycemic Homeostasis Study | 2027-01-01 |
| NCT07007676Shanghai 6th People's HospitalEffect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes | 2027-02-28 |
| NCT07156370Shanghai 6th People's HospitalSalivary Cortisol and Hypercortisolism in Type 2 Diabetes | 2027-06-30 |
| NCT06936657Shanghai 6th People's HospitalIntervention Effects of Optimized Carbohydrate Diet in Patients With Type 2 Diabetes | 2027-06-30 |
| NCT07414277Shanghai 6th People's HospitalCGM for Insulin-Treated T2DM During Post-Discharge Transition | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the clinical value of salivary 1,5-anhydroglucitol (1,5-AG) and assess a novel noninvasive detection approach in individuals with and without type 2 diabetes. Additionally, the study will examine the relationships of salivary 1,5-AG with serum 1,5-AG and continuous glucose monitoring (CGM) measures of short-term glycemic control and fluctuations.
Serum 1,5-anhydroglucitol (1,5-AG) is a marker of short-term glycemic status and is particularly sensitive to recent hyperglycemic excursions. Saliva offers a noninvasive and convenient alternative for repeated metabolic monitoring, but the clinical application of salivary 1,5-AG has been limited by challenges in detection accuracy and standardization. This study therefore aims to evaluate the clinical value of salivary 1,5-AG and a novel noninvasive detection approach. First, the study will assess salivary 1,5-AG levels and compare the novel detection approach with reference measurements. Second, it will evaluate the relationships of salivary 1,5-AG with serum 1,5-AG and continuous glucose monitoring (CGM) metrics to determine its potential for reflecting short-term glycemic fluctuations and glycemic control.
The participants are enrolled from the Department of Endocrinology and Metabolism from Shanghai Sixth People's Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation Between Salivary 1,5-Anhydroglucitol and Glycemic Levels
Salivary 1,5-anhydroglucitol (1,5-AG) will be measured by liquid chromatography-mass spectrometry or enzymatic assay. Glycemic levels will be assessed by fasting plasma glucose (mmol/L), glycated hemoglobin A1c (HbA1c, %), and glycated albumin (GA, %). Pearson or Spearman correlation coefficients will be used to assess their correlations with salivary 1,5-AG.
Time frame: Screening
Correlation Between Salivary and Serum 1,5-Anhydroglucitol Levels
Salivary 1,5-AG will be measured by LC-MS or enzymatic assay, and serum 1,5-AG will be measured by enzymatic assay. Pearson or Spearman correlation coefficients will be calculated.
Time frame: Screening
Correlation Between Salivary 1,5-Anhydroglucitol and Continuous Glucose Monitoring Metrics
Salivary 1,5-AG will be measured by LC-MS or enzymatic assay. CGM metrics will include time in range (TIR), time in tight range (TITR), and time above range (TAR), expressed as percentages.
Time frame: One week
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai 6th People's Hospital